Growth & profitability
- Revenue has grown 7.6% per year over the past 5 years.
Financial health
- Total debt ($3.8B) exceeds cash ($545M); net debt is $3.2B.
- Total debt has grown slower than revenue (-9.3% vs 7.6% per year).
ELAN Financials Elanco Animal Health Inc
10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $4.7B | -$232M | 55.0% | 0.0% | $284M | $3.8B | $545M |
| 2024 | $4.4B | $338M | 54.9% | 0.0% | $394M | $4.3B | $468M |
| 2023 | $4.4B | -$1.2B | 56.3% | 0.0% | $131M | $5.8B | $352M |
| 2022 | $4.4B | -$78M | 56.6% | 0.0% | $281M | $5.8B | $345M |
| 2021 | $4.8B | -$483M | 55.2% | 0.0% | $324M | $6.3B | $638M |
| 2020 | $3.3B | -$574M | 49.1% | 0.0% | -$176M | $6.1B | $495M |
| 2019 | $3.1B | $68M | 52.1% | 0.0% | $84M | $2.4B | $334M |
| 2018 | $3.1B | $87M | 48.7% | 0.0% | $353M | $2.5B | $475M |
| 2017 | $2.9B | -$311M | 48.3% | 0.0% | $75M | $0 | $323M |
| 2016 | $2.9B | -$48M | 51.6% | 0.0% | $46M | — | — |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $1.4B | $57M | 57.3% | 0.0% | -$38M | $3.7B | $428M |
| Dec '25 | $1.1B | -$276M | 51.5% | 0.0% | $46M | $3.8B | $545M |
| Sep '25 | $1.1B | -$34M | 53.4% | 0.0% | $127M | $3.8B | $505M |
| Jun '25 | $1.2B | $11M | 57.5% | 0.0% | $180M | $4.0B | $539M |
| Mar '25 | $1.2B | $67M | 57.3% | 0.0% | -$69M | $4.4B | $487M |
| Dec '24 | $1.0B | -$8M | 50.9% | 0.0% | $130M | $4.3B | $468M |
| Sep '24 | $1.0B | $364M | 52.2% | 0.0% | $120M | $4.4B | $490M |
| Jun '24 | $1.2B | -$50M | 58.2% | 0.0% | $166M | $4.3B | $416M |
| Mar '24 | $1.2B | $32M | 57.3% | 0.0% | -$22M | $5.8B | $345M |
| Dec '23 | $1.0B | -$141M | 50.1% | 0.0% | $116M | $5.8B | $352M |
| Sep '23 | $1.1B | -$1.1B | 54.4% | 0.0% | $165M | $5.9B | $369M |
| Jun '23 | $1.1B | -$97M | 58.9% | 0.0% | $19M | $6.1B | $367M |
| Mar '23 | $1.3B | $103M | 60.7% | 0.0% | -$169M | $6.0B | $318M |
| Dec '22 | $985M | -$54M | 54.5% | 0.0% | -$53M | $5.8B | $345M |
| Sep '22 | $1.0B | -$65M | 54.0% | 0.0% | $163M | $5.9B | $460M |
| Jun '22 | $1.2B | -$10M | 58.8% | 0.0% | $286M | $6.1B | $507M |
| Mar '22 | $1.2B | $51M | 58.5% | 0.0% | -$81M | $6.1B | $342M |
| Dec '21 | $1.1B | -$105M | 54.1% | 0.0% | $157M | $6.3B | $638M |
| Sep '21 | $1.1B | -$108M | 55.6% | 0.0% | $64M | $6.3B | $453M |
| Jun '21 | $1.3B | -$206M | 56.9% | 0.0% | $132M | $6.1B | $580M |
Valuation over time
How the market has priced ELAN against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has risen from 17.9× (Dec '24) to 34.4× (Nov '25).
- The price-to-sales ratio has risen from 1.1× (Mar '23) to 2.6× (Jun '26).
P/E
P/S
Frequently asked questions
Is ELAN growing its revenue and profit?
Over the past 5 years, Elanco Animal Health Inc's revenue has grown 7.6% per year. These are computed facts, not advice.
How much debt does ELAN have?
As of FY2025, Elanco Animal Health Inc reported $3.8B of total debt against $545M of cash.
What is ELAN's profit margin?
In FY2025, gross margin was 55.0%, operating margin —, and net margin -4.9%.
What is ELAN's P/E ratio?
As of Jun '26, Elanco Animal Health Inc traded at a price-to-earnings ratio of about 34.4× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.